EOS imaging announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new generation imaging system, EOSedge. Receipt of FDA 510(k) clearance follows the commercial launch of EOSedge in Europe, Canada and Australia earlier this week. The new system will be unveiled at the upcoming Radiological Society of North America (RSNA) 2019 Annual Meeting starting on December 1st, in Chicago. EOSedge is the first general X-ray system powered by a high-resolution photon counting detector, delivering optimal image quality for outstanding musculoskeletal imaging exams. EOSedge features new Flex Dose™ technology to modulate radiation dose along the patient’s body, as well as an open cabin with a motorized, enlarged patient platform to facilitate easy and comfortable access for a broad range of patients to deliver larger fields of examination. EOSedge will strengthen the portfolio of the Company, with the first-generation EOS® system continuing to be part of the EOS imaging offering. Both EOSedge and the first-generation EOS system are designed to work seamlessly with the Advanced Orthopedic Solutions, which include 3DServices, EOSapps 3D surgical planning for spine, hip and knee as well as EOSlink™, which delivers the EOS surgical plan into the operating room to be used with advanced surgical technologies.